Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...

The gray portion of this schematic represents a nanodisc, where for the first time researchers were able to replicate the native membrane environment (red dots) of a T-cell receptor (cyan). One of the ...

Scientists at École Polytechnique Fédérale Lausanne (EPFL), and at UNIL-CHUV, University Hospital Lausanne (CHUV) and University of Lausanne (UNIL) have developed a computational method to create ...

Immune checkpoint pathways regulate T cell function and play pivotal roles in the treatment of both cancer and autoimmune diseases. One key component of these pathways is Lymphocyte Activation Gene 3 ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

To enhance CAR T therapies, scientists are actively studying TCR signaling and T-cell exhaustion mechanisms to improve CAR T persistence and function. Additionally, there is a growing trend towards ...

A phase 1, first-in-human study of IB-T101, an OUTLAST CAR-T product for the treatment of CD70-positive clear cell renal carcinoma. A phase I study of AFNT-211, autologous CD4+ and CD8+ T cells ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

Immune checkpoint pathways regulate T cell function and play pivotal roles in the treatment of both cancer and autoimmune diseases. One key component of these pathways is Lymphocyte Activation Gene 3 ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...